http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Pro
-
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
-
MilliporeSigma Gains Leading Perfusion Micro-Bioreactor with Erbi Biosystems Acquisition
-
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
-
Merck Announces First-Quarter 2023 Dividend
-
Merck (MRK) Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint
-
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
-
Disney, Imago BioSciences rise premarket; Coinbase, Carvana fall
-
Merck (MRK) Acquires Imago BioSciences (IMGO) for $36/sh or $1.35B
-
Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference
-
Merck to Acquire Imago BioSciences, Inc.
-
MilliporeSigma Invests $ 286 Million in U.S. Drug Safety Testing Capacity
-
Merck's (MRK) LYNPARZA in Combination With Abiraterone and Prednisone or Prednisolone Recommended for Approval in EU
-
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prost
-
Portage Biotech (PRTG) Announces Clinical Trial Collaboration Agreement with Merck (MRK)
-
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies
-
Veeva Systems (VEEV) and Merck (MRK) Enter Long-Term Strategic Partnership
-
Veeva and Merck Form Long-Term Strategic Partnership
-
Merck Announces Third-Quarter 2022 Financial Results
-
Merck (MRK) Announces Robert M. Davis to Succeed Kenneth C. Frazier as Chairman
-
Robert M. Davis to Succeed Kenneth C. Frazier as Chairman of Merck
-
Merck (MRK) Granted Expanded EU VAXNEUVANCE Indication to Include Infants, Children and Adolescents
-
European Commission Expands Merck’s VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Indication to Include Infants, Children and Adolescents
-
Merck (MRK) Reports Positive Phase 3 Data of PREVYMIS for Prevention of Cytomegalovirus Disease
-
Merck’s PREVYMIS™ Demonstrates Efficacy in Phase 3 Study for Prevention of Cytomegalovirus Disease in Adults After Kidney Transplantation
-
Merck Animal Health Launches Sure Petcare Animo® GPS
-
Merck and the Bill & Melinda Gates Medical Research Institute Announce Licensing Agreement for Novel Tuberculosis Antibiotic Candidates
-
Merck Recognized on Fortune’s 2022 Change the World List for Expanding Access to HPV Vaccines
-
Merck (MRK) Reports Positive Top-line Results from Pivotal Phase 3 STELLAR Trial of Sotatercept
-
Merck Announces Positive Top-line Results from Pivotal Phase 3 STELLAR Trial Evaluating Sotatercept for the Treatment of Adults with Pulmonary Arterial Hypertension (PAH)
-
Merck (MRK) and Ridgeback Biotherapeutics Provide Update on New Studies of LAGEVRIO
-
Merck and Ridgeback Biotherapeutics Provide Update on New Clinical and Non-Clinical Studies of LAGEVRIO™ (molnupiravir)
-
MilliporeSigma Announces a Boost in Commercial Capacity in France as Part of New Millipore® CTDMO Services
-
Merck (MRK) Announces U.S. Court of Appeals for Federal Circuit Rules in Favor of it in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
-
U.S. Court of Appeals for the Federal Circuit Rules in Favor of Merck in Sitagliptin Dihydrogen Phosphate Patent Lawsuit
-
Merck to Hold Third-Quarter 2022 Sales and Earnings Conference Call October 27
-
Merck Animal Health Completes Minority Investment in LeeO Precision Farming
-
Merck (MRK) KEYTRUDA Granted Four New Approvals in Japan
-
Merck’s KEYTRUDA® (pembrolizumab) Receives Four New Approvals in Japan, Including in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
-
Merck Animal Health (MRK) to Acquire Vence
-
Merck Animal Health to Acquire Vence
-
Merck (MRK) Announces Court Ruling in Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
-
LYNPARZA® (olaparib) Approved in China as First-Line Maintenance Treatment With Bevacizumab for Homologous Recombination Deficient (HRD)-Positive Advanced Ovarian Cancer
-
U.S. District Court Rules In Favor of Merck in Sitagliptin Phosphate Patent Lawsuit
-
Merck (MRK) to Initiate New Phase 3 Trial with Lower Dose of Daily Oral Islatravir with Doravirine for Treatment of People with HIV-1 Infection
-
Merck to Initiate New Phase 3 Clinical Program with Lower Dose of Daily Oral Islatravir in Combination with Doravirine for Treatment of People with HIV-1 Infection
-
Merck (MRK) Receives Positive CHMP Opinion for VAXNEUVANCE
-
Merck (MRK) Receives Positive CHMP Opinion for VAXNEUVANCE
-
Merck Receives Positive CHMP Opinion for VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) in Infants and Children
-
Seagen (SGEN), Merck (MRK) and Astellas Report Results of Trial Investigating PADCEV

